

The **Planners and Managers** reported the following financial relationships they have with ineligible companies related to the content of this CME activity:

Name of Planner/Manager	Role	Reported Financial Relationship
Tracy Batchelor, MD	Planner	Nothing to Disclose
Mustafa Khasraw, MD	Planner	Contracted Research: BMS, AbbVie (ended), Daiichi Sankyo, BioNTech, Celldex, Astellas, CNS Pharmaceuticals, Immorna Therapeutics, Specialized Therapeutics. Honoraria JAX lab, Johnson & Johnson, Voyager therapeutics, George Clinical, GSK, Novocure. Advisory Board: Janssen (ended), Ipsen (ended), Roche (ended)
Priya Kumthekar, MD	Planner	Consulting Fee: Enclear Therapies, Affinia Therapeutics, Biocept, Janssen, Sinetica (ended), Bioclinica, Novovure, Mirati (ended), Orbus Therapeutics (ended). Contracted Research Genentech, Novocure, DNATRIX, Orbus Therapeutics (ended). Equity: Enclear-ended 12/5/22.
Adrienne Boire, MD, PhD	Planner	Nothing to Disclose
Hussein Tawbi, MD, PhD	Planner	Consulting Fee: Bristol Myers-Squibb, Genentech, Novartis, Merck, Boxer Capital, Karyopharm, Iovance, Eisai, Jazz Pharmaceuticals, Medicenna. Contracted Research: Bristol Myers-Squibb, Genentech, Novartis, Merck, Eisai, GlaxoSmith Kline, EMD Serono, Dragonfly Therapeutics, RAPT Therapeutics.
Priscilla Brastianos, MD	Planner	Consulting Fee: Sintetica, ACI (Advise, Connect, Inspire), Voyager Therapeutics, SK Life Sciences, Genentech-Roche, Angiochem, Tesaro, ElevateBio, Pfizer Pharmaceuticals. Honoraria: Pfizer. Speaker's Bureau Medscape, BioImpact Capital and/or MPM Asset Management, Merck. Other- Grant/Research Support to MGH: Mirati, Kinnate, Lilly, Bristol-Myers Squibb, Merck
Sarah Goldberg, MD, MPH	Planner	Consulting Fee: AstraZeneca, Boehringer, Ingelheim, Bristol-Myers Squibb, Genentech, Amgen, Blueprint Medicine, Sanofi Genzyme, Daiichi-Sankyo, Regeneron, Takeda, Janssen. Contracted Research: Astra Zeneca, Boehringer, Ingelheim, Mirati.

Michael Platten, MD, PhD	Planner	Owner/Founder: Tcelltech. Consulting Fee: Bayer, Pasinthea, Servier
Stephen Bagley, MD	Planner	Consulting Fee: Kiyatec. Contracted Research: Incyte, Eli Lilly, GSK, Novocure, Tempus, C2i Genomics, Tmunity
Evanthia Galanis, MD	Planner	Consulting Fee/Advisory Board: Karyopharm Therapeutics, Inc. (DSMB, compensation to employer), Kiyatec, Inc. (personal compensation), Boston Scientific (DMC, compensation to employer). Contracted Research: Grant/Research/Clinical Trial Funding (to Mayo): Celgene Denovo Biopharma MedImmune, Inc. Servier Pharmaceuticals LLC. Honoraria: Advisory Board Karyopharm Therapeutics, Inc. (DSMB, compensation to employer) Kiyatec, Inc. (personal compensation) Boston Scientific (DMC, compensation to employer).
Vinai Gondi, MD	Planner	Nothing to Disclose
Jona Hattangadi-Gluth, MD	Planner	Honoraria: Aptitude Health (ended).
Sara Hurvitz, MD	Planner	Research Grant paid to institution: Ambrx, Amgen, Arvinas, Astra Zeneca, Bayer, Cytomx, Daiichi-Sankyo, Dantari, Dignitana, Genentech/Roche, G1-Therapeutics, Gilead, GSK, Immunomedics, Eli Lilly, Macrogenics, Novartis, OBI Pharma, Orinove, Pfizer, Phoenix Molecular Designs, Ltd., Pieris, PUMA, Radius, Samumed, Sanofi, Seattle Genetics/Seagen, Zymeworks, Greenwich life Sciences, Orum

Emilie Le Rhun, MD, PhD	Planner	Consulting Fee: Bayer, Janssen, Leo Pharma, Pierre Fabre, Seagen, Servier. Contracted Research: BMS. Honoraria: Astra Zeneca, Pierre Fabre
Nancy Lin, MD	Planner	Consulting Fee: Puma, Seattle Genetics, Daichii-Sankyo, AstraZeneca, Denali Therapeutics, Prelude Therapeutics, Olema Pharmaceuticals, Aleta BioPharma, Affinia Therapeutics, Voyager Therapeutics, Janssen, Blueprint Medicines, Artera Inc. Contracted Research: Genentech, Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals, Olema Pharmaceuticals, AstraZeneca
Minesh Mehta, MD	Planner	Board of Directors- Xcision (unremunerated). Advisory Board- Mevion Technological Advisory Board. Ended relationships : Consultant-Kazia, Novocure, Sap, Xoft. Stock- Chimerix (disposed of). Board of Directors-Oncoceutics. Stock Options Oncoceutics relinquished
Josh Neman, PhD	Planner	Nothing to Disclose
Solmaz Sahebjam, MD	Planner	Contracted Research (all ended): Merk, Britsol-Myers Squibb, Brooklyn Immuno Therapeutics
Debra Nana Yeboa, MD	Planner	Nothing to Disclose
Ayal Aizer, MD	Planner	Consulting Fee: Seagen, Novartis. Contracted Research: Varian, NHT
Stephen Bagley, MD	Planner	Consulting Fee: Kiyatec. Contracted Research: Incyte, Eli Lilly, GSK, Novocure, Tempus, C2i Genomics, Tmunity
Benjamin Ellingson, PhD	Planner	Consulting Fee: Medicana, MedQIA, Servier, Siemens, Imaging Endpoints, Chimerix, Sumitomo Sainippon Pharma Oncology, ImmunoGenesis, Ellipses Pharma, Monteris, Neosoma, Sagimet Biosciences, Sapience Therapeutics, Orbus Therapeutics. Contracted Research: Siemens, Neosoma, Medicenna, MedQIA
Peter Fecci, MD, PhD	Planner	Consulting Fee: Monteris Medical, LLC
Elizabeth Gerstner, MD	Planner	Data Safety Monitoring Board: Midatech Pharma
Isabella Glitza, MD, PhD	Planner	Consulting Fee: BMS, Novartis, Pfizer, Leal Therapeutics,

		Midatech. Contracted Research: BMS, Merck, Pfizer. Honoraria: Novartis.
Maggie Johnson, MD, MPH	Planner	Nothing to Disclose
Jason Johnson, MD	Planner	Consulting Fee: Inform AI (ended), Kura oncology, BioClinica. Contracted Research: Blue Earth Diagnostics
Tim Kaufman, MD, MS	Planner	Stock Options Holder: SpineThera
Eudocia Quant-Lee, MD, MPH	Planner	Nothing to Disclose
Seema Nagpal, MD	Planner	Consulting Fee: EnClear Therapeutics, Biocept, Novocure, Mirati (ended), Pyramid Bioscience (ended), Kiyatec (ended) and Midatech (ended), Seattle Genetics (ended)
Elena Pentsova, MD	Planner	Contracted Research : Y-mAb Therapeutics, Inc.
Rifaquat Rahman, MD	Planner	Consulting Fee: St. Lucia Consulting
Akanksha Sharma, BS, MD	Planner	Consulting Fee: National Brain Tumor Society Quality of Life Advisory Committee. Contracted Research: Chimerix, Incyte, Novocure, Apollomics, Oblato. Honoraria: Project Ronin (ended)
Riccardo Soffiatti, MD	Planner	Nothing to Disclose
Yoshie Umemura, MD, MS	Planner	Consulting Fee: Tempus (ended). Contracted Research (all ended): BTG International, Inc., Ono Pharmaceutical Company, Chimerix, Agios Pharmaceuticals, Inc., Oncoceutics.
Manuel Valiente, PhD	Planner	Research Grant: Astra Zeneca
Mike Vogelbaum, MD, PhD	Planner	Consulting Fee: Olympus, Midatech, Chimerix, Plus Therapeutics. Contracted Research: Oncosynergy, Infuseon, DeNovo, Chimerix, Celgene
Jeffrey Wefel, PhD	Planner	Consulting Fee: Angiochem (ended), Bayer, GT Medical Technology, Juno (ended), Novocure, Roche (ended), Vanquish Oncology (ended)
Michael Weller, MD	Planner	Consulting Fee: Bayer, Curevac, Medac, Novartis, Novocure, Orbus, Philogen, Roche, Sandoz. Contracted Research: Quercis, Versameb. Honoraria: Curevac, Novocure, Orbus.
Patrick Wen, MD	Planner	Consulting Fee: Astra Zeneca, Black Diamond, Celularity, Chimerix, Day One Bio, Genenta, Glaxo Smith Kline, Merck, Mundipharma, Novartis, Novocure, Nuvation Bio, Prelude Therapeutics, Sapience, Servier, Sagimet, Vascular Biogenics, VBI Vaccines. Contracted Research: Astra Zeneca, Black Diamond, Bristol Meyers Squibb, Celgene, Chimerix, Eli Lilly, Erasca, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Servier, Vascular Biogenics, VBI Vaccines

Debra Nana Yeboa, MD	Planner	Nothing to Disclose
Charles Haynes	Manager	Nothing to Disclose
Tara Mammoser	Manager	Nothing to Disclose
MeLesia Ritterhouse	Manager	Nothing to Disclose
Angie Ames	Manager	Nothing to Disclose
Caroline Noor	Manager	Nothing to Disclose
Ginger Vazquez	Manager	Nothing to Disclose
Shelley Pressley	Manager	Nothing to Disclose
Amelia Hutsell	Manager	Nothing to Disclose
Gabrielle Griffin	Manager	Nothing to Disclose
Olivia Ing	Manager	Nothing to Disclose
Maloree Burgin	Manager	Nothing to Disclose
Megan Johnston	Manager	Nothing to Disclose
Kristina Knight	Manager	Nothing to Disclose
Kristin Odom	Manager	Nothing to Disclose
Carolyn Loch	Manager	Nothing to Disclose

The **Faculty** reported the following financial relationships they have with ineligible companies related to the content of this CME activity:

Name of Faculty	Role	Reported Financial Relationship
Don Nguyen, PhD, BS	Faculty	Contracted Research: AstraZeneca
Jonathan Kipnis, PhD	Faculty	Nothing to Disclose
Humsa Venkatesh, PhD	Faculty	Nothing to Disclose
Maxine Umeh Garcia, PhD, MSc	Faculty	Nothing to Disclose
Alexandra Zimmer, MD, MSc	Faculty	Honoraria: Medscape (ended)
Nancy Lin, MD	Faculty	Consulting Fee: Puma, Seattle Genetics, Daichii-Sankyo, AstraZeneca, Denali Therapeutics, Prelude Therapeutics, Olema Pharmaceuticals, Aleta BioPharma, Affinia Therapeutics, Voyager Therapeutics, Janssen, Blueprint Medicines, Artera Inc. Contracted Research: Genentech, Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals, Olema Pharmaceuticals, AstraZeneca

Seema Nagpal, MD	Faculty	Consulting Fee: EnClear Therapeutics, Biocept, Novocure, Mirati (ended), Pyramid Bioscience (ended), Kiyatec (ended) and Midatech (ended), Seattle Genetics (ended)
Jona Hattangadi-Gluth, MD	Faculty	Honoraria: Aptitude Health (ended).
Jeffrey Wefel, PhD	Faculty	Consulting Fee: Angiochem (ended), Bayer, GT Medical Technology, Juno (ended), Novocure, Roche (ended), Vanquish Oncology (ended)
Stephen Bagley, MD	Faculty	Consulting Fee: Kiyatec. Contracted Research: Incyte, Eli Lilly, GSK, Novocure, Tempus, C2i Genomics, Tmunity
Mustafa Khasraw, MD	Faculty	Contracted Research: BMS, AbbVie (ended), Daiichi Sankyo, BioNTech, Celldex, Astellas, CNS Pharmaceuticals, Immorna Therapeutics, Specialized Therapeutics. Honoraria JAX lab, Johnson & Johnson, Voyager therapeutics, George Clinical, GSK, Novocure. Advisory Board: Janssen (ended), Ipsen (ended), Roche (ended)
Priya Kumthekar, MD	Faculty	Consulting Fee: Enclear Therapies, Affinia Therapeutics, Biocept, Janssen, Sinetica (ended), Bioclinica, Novovure, Mirati (ended), Orbus Therapeutics (ended). Contracted Research Genentech, Novocure, DNATRIX, Orbus Therapeutics (ended). Equity: Enclear-ended 12/5/22.
Jan Remsik, PharmD, PhD	Faculty	Nothing to Disclose
Shawn Shun-Cheng Li, PhD	Faculty	Nothing to Disclose
Michael Taylor, MD, PhD	Faculty	Nothing to Disclose
Adrienne Boire, MD, PhD	Faculty	Nothing to Disclose
Roberta Ruda, MD	Faculty	Nothing to Disclose
Jonathan Yang, MD, PhD	Faculty	Consulting Fee: Galera Therapeutics, Nanocan Therapeutics, AstraZeneca. Contracted Research: AstraZeneca, Kazia Therapeutics, X-Rad Therapeutics, Debiopharm, Biocept.
Jessica Wilcox, MD	Faculty	Consulting Fee: Apellis Pharmaceuticals
Elena Pentsova, MD	Faculty	Contracted Research : Y-mAb Therapeutics, Inc.
Benjamin Ellingson, PhD	Faculty	Consulting Fee: Medicana, MedQIA, Servier, Siemens, Imaging Endpoints, Chimerix, Sumitomo Sainippon Pharma Oncology, ImmunoGenesis, Ellipses Pharma, Monteris, Neosoma, Sagimet Biosciences, Sapience Therapeutics, Orbus Therapeutics. Contracted Research: Siemens, Neosoma, Medicenna, MedQIA
Alessia Pellerino, PhD	Faculty	Nothing to Disclose
Akshata Anchan, PhD	Faculty	Nothing to Disclose
Vanessa Souza, PhD Candidate	Faculty	Nothing to Disclose
Vivek Narayan, MD, MS	Faculty	Consulting Fee: Janssen, Merck, Regeneron, Exelixis, Pfizer, Bristol Myers Squibb, AstraZeneca, Myovant. Contracted Research: Janssen, Merck, Regeneron, Pfizer, Bristol Myers Squibb, TMunity Therapeutics. Honoraria: Pfizer.

Jessica Taylor, PhD	Faculty	Nothing to Disclose
Sheila Singh, MD, PhD	Faculty	Consulting Fee: Century Therapeutics, Blackstone Group. Contracted Research: Novartis venture fund, 28/7, Admare Bioinnovations, PTV Therapeutics, Century Therapeutics. Stock Options Holder: Century Therapeutics, Stempharm.
Chan Wee Woo, MD	Faculty	Nothing to Disclose
Haley Perlow, MD	Faculty	Nothing to Disclose
Joseph Sia, MBChB, PhD	Faculty	Nothing to Disclose
Jessica Waibl Polania, PhD Candidate	Faculty	Nothing to Disclose
Benjamin Lu, MD	Faculty	Nothing to Disclose
Renato Guerreiri, MD-PhD Candidate	Faculty	Nothing to Disclose
Ana Rita Nobre, PhD	Faculty	Nothing to Disclose
James Reinecke, MD	Faculty	Nothing to Disclose
Jenna Snyder, PhD Candidate	Faculty	Nothing to Disclose
Yolanda Pina, MD	Faculty	Nothing to Disclose
Shao-Lun Lu, MD, PhD	Faculty	Nothing to Disclose
Hannah Wilding, BS, MD Candidate	Faculty	Nothing to Disclose
David Piccioni, MD, PhD	Faculty	Nothing to Disclose
Lucy Boyce Kennedy, MD	Faculty	Nothing to Disclose
Akansha Sharma, BS, MD	Faculty	Consulting Fee: National Brain Tumor Society Quality of Life Advisory Committee. Contracted Research: Chimerix, Incyte, Novocure, Apollomics, Oblato. Honoraria: Project Ronin (ended)
Minesh Mehta, MD	Faculty	Board of Directors- Xcision (unremunerated). Advisory Board- Mevion Technological Advisory Board. Ended relationships : Consultant-Kazia, Novocure, Sap, Xoft. Stock- Chimerix (disposed of). Board of Directors-Oncocoetics. Stock Options Oncocoetics relinquished
Peter Fecci, MD, PhD	Faculty	Consulting Fee: Monteris Medical, LLC
Isabella Glitza, MD, PhD	Faculty	Consulting Fee: BMS, Novartis, Pfizer, Leal Therapeutics, Midatech. Contracted Research: BMS, Merck, Pfizer. Honoraria: Novartis.
Jessica Wilcox, MD	Faculty	Consulting Fee: Apellis Pharmaceuticals
Adrienne Boire, MD, PhD	Faculty	Nothing to Disclose

The Moderators reported the following financial relationships they have with ineligible companies related to the content of this CME activity:

Name of Moderator	Role	Reported Financial Relationship
Adrienne Boire, MD, PhD	Moderator	Nothing to Disclose

Sarah Goldberg, MD, MPH	Moderator	Consulting Fee: AstraZeneca, Boehringer, Ingelheim, Bristol-Myers Squibb, Genentech, Amgen, Blueprint Medicine, Sanofi Genzyme, Daiichi-Sankyo, Regeneron, Takeda, Janssen. Contracted Research: Astra Zeneca, Boehringer, Ingelheim, Mirati.
Josh Neman Ebrahim, PhD	Moderator	Nothing to Disclose
Aram Modrek, MD, PhD	Moderator	Contracted Research: Novocure
Hussein Tawbi, MD, PhD	Moderator	Consulting Fee: Bristol Myers-Squibb, Genentech, Novartis, Merck, Boxer Capital, Karyopharm, Iovance, Eisai, Jazz Pharmaceuticals, Medicenna. Contracted Research: Bristol Myers-Squibb, Genentech, Novartis, Merck, Eisai, GlaxoSmith Kline, EMD Serono, Dragonfly Therapeutics, RAPT Therapeutics.
Minesh Mehta, MD	Moderator	Board of Directors- Xcision (unremunerated). Advisory Board- Mevion Technological Advisory Board. Ended relationships : Consultant-Kazia, Novocure, Sap, Xoft. Stock-Chimerix (disposed of). Board of Directors-Oncocentrics. Stock Options Oncocentrics relinquished
Terry Burns, MD, PhD	Moderator	Consulting Fee: Alector, Predicine. Contracted Research: Aminex Therapeutics, SonALAsense, Insightec, J-pharma, Joanneum Research, Codman, Abbvie, Predicine. Stock Options Holder: Neurametrix.
Howard Colman, MD, PhD	Moderator	Consulting Fee: Best Doctors/Teladoc, Orbus Therapeutics, Bristol Myers Squibb, Regeneron, Novocure, PPD/Chimerix. Contracted Research: Orbus, GCAR, Array BioPharma, Karyopharm Therapeutics, Nuvation Bio, Bayer, Bristol Meyer Squib, Sumitomo Dainippon Pharma Oncology, Samus Therapeutics, Erasca
Diana Cittelly, PhD	Moderator	Nothing to Disclose
Susan Chang, MD	Moderator	Consulting Fee: AstraZeneca (ended)
Saul Priceman, PhD	Moderator	Consulting Fee: Imugene Ltd, Bayer, Celularity, Port Therapeutics, Mustang, Adicet Bio. Stock Options Holder: Imugene Ltd, Celularity, Port Therapeutics, Adicet Bio.
Inna Smalley, PhD	Moderator	Nothing to Disclose
Emilie LeRhun, MD, PhD	Moderator	Consulting Fee: Bayer, Janssen, Leo Pharma, Pierre Fabre, Seagen, Servier. Contracted Research: BMS. Honoraria: Astra Zeneca, Pierre Fabre
Barbara O'Brien, MD	Moderator	Consulting Fee: Plus Therapeutics
Caroline Chung, MD, MSc	Moderator	Contracted Research: Siemens Healthineers, RaySearch Laboratories

